Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $659,481.48 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock in a transaction on Friday, June 12th. The shares were sold at an average price of $69.72, for a total value of $659,481.48. Following the completion of the transaction, the senior vice president owned 17,294 shares of the company’s stock, valued at approximately $1,205,737.68. The trade was a 35.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $27,527.55.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Down 1.5%

ORKA stock traded down $1.03 during midday trading on Monday, reaching $68.86. The stock had a trading volume of 1,002,319 shares, compared to its average volume of 1,071,721. The firm has a market cap of $4.15 billion, a price-to-earnings ratio of -35.49 and a beta of -0.25. The business has a fifty day simple moving average of $63.40 and a two-hundred day simple moving average of $44.04. Oruka Therapeutics, Inc. has a twelve month low of $10.77 and a twelve month high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, equities analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, April 30th. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Wedbush set a $165.00 target price on Oruka Therapeutics in a research note on Monday, April 27th. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $131.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new position in shares of Oruka Therapeutics during the first quarter worth about $2,505,000. JPMorgan Chase & Co. boosted its position in shares of Oruka Therapeutics by 567.7% during the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock worth $173,000 after buying an additional 13,115 shares during the period. Legal & General Group Plc acquired a new position in shares of Oruka Therapeutics during the second quarter worth about $28,000. Rhumbline Advisers acquired a new position in shares of Oruka Therapeutics during the second quarter worth about $320,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Oruka Therapeutics during the second quarter worth about $96,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.